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PREVALENS DAN FAKTOR RISIKO DISFUNKSI KOGNITIF 
DALAM KALANGAN PESAKIT DIABETES MELITUS DI IRAQ 
 
ABSTRAK 
 
Diabetes melitus merupakan suatu penyakit metabolik kronik yang terkenal 
berdasarkan komplikasinya yang banyak.Ia merupakan penyakit yang boleh diurus 
sendiri atau swaurus (self-managed disease), yang memerlukan kognisi intak untuk 
mengekalkan kualiti hidup yang baik. Disfungsi kognitif adalah perubahan 
neurodegeneratif yang boleh dikaitkan dengan diabetes melitus.Ia dianggap sebagai 
tahap pertama penyakit dementia dan Alzheimer, yang bersama-sama dengan 
diabetes merupakan masalah kesihatan prevalens global yang semakin. Kajian ini 
mengkaj perkaitan yang tidak jelas antara diabetes melitus dan disfungsi 
kognitif.Kajian ini berurusan dengan prevalens disfungsi kognitif dalam kalangan 
diabetes.Ia juga turut membandingkan insidens atau keberlakuan gangguan kognitif 
(cognitive impairment) dalam diabetes jenis 1 dan 2. Disamping itu, turut dikaji 
pengaruh diabetes sebagai suatu penyakit kronik, komplikasinya, serta rawatan 
terhadap prestasi kognitif.Suatu metodologi kawalan rentas - kes digunakan dalam 
usaha mengekalkan objektif kajian.Dua jenis peralatan digunakan untuk menilai 
disfungsi kognitif, iaitu Pemeriksaan Status Miniminda (Mini-Mental Status 
Examination, MMSE), dan Penilaian Kognitif Montreal (Montreal Cognitive 
Assessment, MoCA). Selepas mengira saiz sampel, seramai 380 orang pesakit 
diabetes, dan 100 orang subjek kawalan yang memenuhi kriteria yang ditetapkan 
terlibat dalam kajian ini.Sebagai suatu subkajian, perkaitan antara status penanda 
pengimejan resonans magnet (magnetic resonance imaging, MRI) otak dan prestasi 
xviii 
 
kognitif dinilai bagi sebilangan peserta yang tertentu. Dapatan kajian menunjukkan 
bahawa berdasarkan penggunaan MMSE, prevalens disfungsi kognitif adalah 16.3% 
bagi pesakit diabetes, dan 7% bagi subjek kawalan. Berdasarkan penggunaan MoCA, 
prevalens disfungsi kognitif adalah 59.2% bagi pesakit diabetes, dan 15% bagi 
subjek kawalan. Dari segi jenis diabetes, tiada perbezaan signifikan ditemui antara 
prestasi kognitif jenis 1 dan 2.Bagi pesakit diabetes, disfungsi kognitif adalah 
berkaitan dengan glisemia yang tidak terkawal, yang diwakili oleh tahap HbAIC 
yang tinggi.Ia juga dikaitkan dengan obesiti (kegemukan) dan kurang senaman serta 
penggunaan suplemen. Dalam kedua-dua kes (MMSE dan MoCA), prestasi kognitif 
yang buruk dikaitkan dengan pesakit yang diberi sulfonilurea bersama-sama dengan 
insulin, prestasi yang baik adalah dalam kalangan pesakit yang menggunakan 
amaryl®, monoterapi insulin atau terapi daripada gabungan metformin-insulin.Akhir 
sekali, terdapat perkaitan yang signifikan di antara disfungsi kognitif dan isyarat 
hiperintesiti yang tidak normal dalam otak.Sebagai kesimpulan, disfungsi kognitif 
mungkin merupakan antara komplikasi diabetes melitus. Justeru, ia sepatutnya diberi 
pertimbangan sewajarnya sebagai suatu keadaan yang memerlukan penilaian klinikal 
serta pelan terapeutik.  
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THE PREVALENCE AND RISK FACTORS OF COGNITIVE 
DYSFUNCTION AMONG PATIENTS WITH DIABETES 
MELLITUS IN IRAQ 
 
ABSTRACT 
 
   Diabetes mellitus is a chronic metabolic disease that is distinguished by many 
complications. It is mainly a self-managed disease that needs intact cognition to 
maintain better quality of life. Cognitive dysfunction is a neurodegenerative changes 
that might be associated with diabetes mellitus. It is considered as the first stage of 
dementia and Alzheimer disease which is together with diabetes are global growing 
prevalence health concerns. This study investigates the unclear relationship between 
diabetes mellitus and cognitive dysfunction. It deals with occurrence of cognitive 
dysfunction among diabetes. It also compares the occurrenceof cognitive impairment 
in type 1 and type 2 diabetes. In addition, it investigates the influence of diabetes as a 
chronic disease, its complication and treatment on cognitive performance. A 
comparative cross-sectional methodology was adopted to achieve the study 
objectives. Two tools were used to evaluate cognitive dysfunction, the Mini-Mental 
Status Examination (MMSE), and Montreal Cognitive Assessment (MoCA). After 
calculating sample size, 380 patients with diabetes, and 100 control subjects who met 
inclusion and exclusion criteria were included in the study. As a sub-study, the 
association between brain magnetic resonance imaging (MRI) marker status and 
cognitive performance was assessed for certain number of participants (n=10 per 
arm). The major findings of this study are that according to MMSE, the prevalence 
of cognitive dysfunction was 16.3% of patients with diabetes and 7% of controls. By 
using MoCA, cognitive dysfunction prevalence was 59.2% of patients with diabetes, 
xx 
 
and 15% of controls. In terms of diabetes types, no significant difference was found 
between the cognitive performance of type 1 diabetes and that of type 2 diabetes. In 
patients with diabetes, cognitive dysfunction was associated with uncontrolled 
glycemia represented by high levels of HbA1c. It is also associated with obesity and 
lack of exercise and supplements use. In both, MMSE and MoCA cases, the worse 
cognitive performance was associated with patients on sulfonylurea in combination 
with insulin, and the best performance was among patients who usedglimepiride 
(amaryl
®
), insulin monotherapy or metformin-insulin combination therapy. Finally, 
there was a significant association between cognitive dysfunction and abnormal 
signal hyperintensities in the brain. In conclusion; cognitive dysfunction might be 
among diabetes mellitus complications list. It should be given consideration as a 
condition that needs to be part of the clinical assessment and the therapeutic plan of 
diabetes mellitus.   
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CHAPTER ONE 
INTRODUCTION 
1.1 Overview 
Diabetes mellitus is a widespread metabolic abnormalities and is characterized by 
hyperglycemia (high blood glucose levels) resulting from discrepancy in insulin 
secretion (type 1 diabetes), resistance to insulin associated with an inadequate 
secretion of insulin, or both (type 2 diabetes) ("Report of the expert committee on the 
diagnosis and classification of diabetes mellitus," 2003). 
During the last decade, studieshave demonstrated that diabetesmellitus might be 
classified to different kinds with various etiologies, althoughpathological 
progressionmight be comparable after the disease onset (Koda- Kimble, Young, 
Kradjan, &Guglielmo, 2005). Type 1 diabetes is caused by the obliteration of beta-
cells in pancreas. This leads to complete insulindeficiency which is known as insulin–
dependent diabetes mellitus (IDDM). Most commonly, type 1 diabetes involveswith 
subjectsnear puberty (Koda- Kimble et al., 2005). Type 1 diabetes is treated by 
injection of insulin to replace absent endogenous form of insulin, diet and exercise 
(Koda- Kimble et al., 2005).  
The other type is type 2 diabetes, a non-insulin-dependent diabetes mellitus 
(NIDDM). This typeoccurs when the pancreas retains part ofpancreaticbeta-cell role, 
but the inconsistentrelease of insulin is inadequate to preserve glucose homeostasis. 
The onset of this type of diabetes is in the adulthood(Howlett, Porte, Allavoine, Kuhn, 
& Nicholson, 2003). Factorsthat affect type 2diabetes development areobesity, 
hereditaryrisk factors,environmental aspect, physical activity, overweight birth and 
gestational diabetes(ADA, 2010).Non-insulin dependentdiabetes is managed by diet, 
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exercise and oral anti-diabetic agents.Insulin is used to treat diabetes type 2when the 
oral treatments fail to maintain glycemiccontrol (Stenman, Melander, Groop, & 
Groop, 1993). Oral diabetes treatment that are used in type 2diabetes include: 
Sulfonylurea; biguanides; α-glucosidase inhibitors;thiazolidenidiones and non-
sulfonylurea insulin secretogogues (Stenman et al., 1993).Type 1 diabetesconsists 5-
10% of diabetes population, while type 2 accounts for 90-95%. The diabetes 
prevalence among adults was found to be 2.8% in 2000 and is estimated to 
beincreased to 4.4% by the year 2030 worldwide(Wild, Roglic, Green, Sicree, & 
King, 2004). 
Bothtypes of diabetes have prognosisof numerous micro- and macro-vascular 
complications, such as retinopathy, nephropathy, peripheral neuropathy, dyslipidemia 
and cardiovascular events. The clinical signs and symptoms in addition to the 
diagnostic methods ofaforementioned complications are established thoroughly 
(ADA, 2005). The development of this chronic disease complications is relianton the 
diabetes duration and the level of metabolic control(ADA, 2002). 
Type 2 is commonly undiagnosed for many years because the symptoms at the 
beginning are not severe enough to provoke evident diabetes symptoms. About half of 
diabetes population may be undiagnosed(ADA, 2005). Yet, such cases are at high 
incidence of showing diabetes complications and other related disorder. Moreover, 
type 2 is a slow onset disorder starting from normal glucose homeostasis, borderline 
hyperglycemia to diabetes(ADA, 2006). Borderline diabetes often develops to full-
blown diabetes with increased complications risks (ADA, 2006). 
Cognitive function is the term used to explainindividual's state of memory, 
attention span and consciousness (including alertness and orientation). Cognitive 
3 
 
functioning had been the subject of many studies in both types of diabetes(Kodl & 
Seaquist, 2008; Munshi et al., 2006). Several cross-sectional and case-control 
researches since 1980s revealed positive associations between diabetes and cognitive 
impairment (Gregg & Brown, 2003). 
1.2 Pathophysiology of Diabetes Mellitus: 
Insulin is considered as amain anabolic hormone thathas a vitaleffect to 
maintaingrowth and the development of tissues. Endogenously, insulin is released by 
the pancreatic β-cell to maintain homeostasis. This biological event take place as 
aresponse toincreased level of circulating glucose and amino acids after food 
ingestion(Moller & Jorgensen, 2009). Insulin regulates circulating glucose level at 
many parts of the body. It reduces hepatic production of glucose bygluconeogenesis 
and glycogenolysis. It also increases the rate of glucose uptake particularly into 
skeletal muscles andfatty tissues(Shulman, 2000). Insulin increaseslipogenesis in liver 
and adipocytes, and decreasesthe release of fatty acid fromadipose tissue (Sesti, 
2006). During fasting, hyperglycemia is caused by abundant basal hepatic glucose 
production as a result of liver resistance to insulin action. Hyperglycemia resulting 
from food ingestion is caused by the dysfunction ofβ-cell in the pancreas (insufficient 
insulin production), hepatic glucose over production and lack of glucose uptake by 
peripheral tissues(Giorgino, Laviola, & Leonardini, 2005). 
Chronic hyperglycemia affects the secretion kineticsfrom the β-cell by time. 
Consequently, tissue sensitivity to insulin will beaffected (glucotoxicity)(Dailey, 
2004). Thus, both impaired insulin action and dysfunctional insulin 
secretionexplaintype 2 diabetes pathogenesis (Giorgino et al., 2005). In PimaIndians 
(Bogardus, 1993) and Mexican Americans (Gulli, Ferrannini, Stern, Haffner, & 
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DeFronzo, 1992), insulinresistance is the primaryexclusive cause. On the other 
hand,β-cell deficiency inwhite populations was the most marked cause during early 
stage diabetesmellitus development (Vaag, Henriksen, Madsbad, Holm, & Beck-
Nielsen, 1995). 
1.3 Treatment 
The most important point in treating hyperglycemia in patients with diabetes isto 
prevent or delay the development of complications of this disease that exist as a 
threatto the quality of life. Three major components to treat type 2 diabetes include: 
diet, pharmacologic therapy (oral hypoglycemicagents, and insulin) and exercise. 
Type 1 diabetes is managed by insulin, diet and increasing physical activity. 
1.3.1 Diet 
The cornerstone of diabetes management is diet and exercise. These two diabetes 
managing ways should be adopted as a first step of diabetes type 2 therapeutic plan 
(ADA, 2010). However, benefits from these interventionsare inadequate for nearly all 
patients with type 2 diabetes (Consoli et al., 2004). 
1.3.2 Pharmacologic therapy 
 
Treatment of diabetes type 1 is insulin plus diet and exercise. Only sulfonylureas as 
well as insulin exist to treat diabetes type 2 untilmid-1990s.Later, metformin, α-
glucosidase inhibitors, thiazolidenidiones andnon-sulfonylureas were introduced to 
the markets after being approved by the FDA (Food and DrugAdministration). Many 
compoundsof various mechanism of actionare under research(Koda- Kimble et al., 
2005). Usually, diabetes type 2patients are prescribed other agentsto managetheir 
diabetes-associated complications such ashypertension, cardiovascular events, 
dyslipidemia,and other chronic illnesses that that may be causedby aging. From this  
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point,it could be said that diabetes type 2treatment should be the simplest, most 
effective, and the safestregimen that treat diabetes and its complicationsproperly 
(ADA, 2008). 
1.3.2(a)α-Glucosidase inhibitors 
The only member belongs to this group is acarbose 25, 50and 100mg and miglitol. 
Theydo not lead toincreasedbody weight(Hong, Xun, & Wutong, 2007). The adverse 
effects that might be caused by this group are diarrhea and bloating. Starting with 
lowest doses and increase it gradually on needis helpful to avoid diarrhea (ADA, 
2006). The mechanism of action of this group is toinhibitcarbohydrates digestion that 
leads todecrease the absorption of glucose (Hong et al., 2007). 
1.3.2(b)Non-sulfonylurea insulin secretagogues 
Repaglinide, and nateglinide, are members of insulin secretion-stimulating group. It 
acts by helping the pancreas produce insulin (Culy & Jarvis, 2001). Repaglinide was 
approved by FDA of United States of America in 1997. The other member 
wasapproved in 2000(Culy & Jarvis, 2001). The intake recommendation of usage of 
this group is to take the doseprior meals immediately and to skip the dose whenever 
the meals is skipped(ADA, 2006). 
1.3.2(c)Sulfonylureas 
Several members of sulfonylureas have been discovered.Members of the first 
generation are: chlorpropamide, Acetohexamide, tolbutamide, and tolazamide (ADA, 
2006). The secondgeneration includes glipizide and glyburide. The third generation is 
represented by Glimipride which was approved in 1997. One of the major adverse 
effects of sulfonylureas is hypoglycemia when insulin production overshoots.This 
adverse effect is found to be lesserassociated with this group compared to insulin 
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(Patlak, 2002). All members have common mechanism of action by stimulating the 
production of insulin by Potassium ATP channel inhibition. Although,each 
memberhave different pharmacokinetics and side effects (Zimmerman, 1997). 
1.3.2(d)Thiazolidenidiones (TZDs) 
Rosiglitazone and pioglitazone received the FDA of the United States approval was 
in 1999, troglitazone which was approvedin 1997 which has been withdrawnfrom 
markets in 2000 due toitseffect of hepatotoxicity effect(Mudaliar & Henry, 2001). 
This group acts by increasingthe utilization of glucose in adipose tissues and skeletal 
muscles. In addition, it decreasesthe hepaticproduction of glucose. This group also 
increasesthe uptake of fatty acid and reduces lipolysis inthe adipose tissue.Eventually, 
these events leads to reduction of postprandial and fasting plasma glucose, andinsulin 
(Olefsky, 2000). Patients with liver dysfunction andmajorcardiac diseases have 
contraindications to this group (O'Moore-Sullivan & Prins, 2002). Most patients on 
TZDs will requirecombination therapy with other anti-diabetic treatment to 
achievethe desired long term glycemic control (Turner, Cull, Frighi, & Holman, 
1999). 
1.3.2(e)Metformin 
Phenformin, the first discovered member of biguanide, was available in 1977. Its 
association with lactic acidosis was the major reason for it to be withdrawn from the 
markets (Koda- Kimble et al., 2005). The only licensed member of biguanide until 
now is metformin (Koda- Kimble et al., 2005). Fortunately, metforminis not 
associated withhypoglycemia as an adverse effect as with sulfonylureas. In addition, it 
is prescribed to overweight patients (with body mass index > 25kg/m
2
) as it does 
notpromote weight gain and it does stimulate the secretion of insulin from pancreas 
7 
 
(Kimmel & Inzucchi, 2005). Itreduces the hepatic glucose production which will lead 
todecrease fasting plasma glucose level (Hundal et al., 2000).Metformin also 
increases the muscle tissue sensitivity to insulin that helps to decrease blood glucose 
concentration. Metformin is contraindicated in conditions such as renal dysfunction, 
liver impairment, pregnancy, stress conditions and other acute illnesses("Type 2 
Diabetes: National Clinical Guideline for Management in Primary and Secondary 
Care (Update)," 2008) 
1.3.2(f)Insulin 
Exogenous insulin is mandatory for patient with diabetes type1survivaldue to the 
almost complete destruction ofpancreatic β-cells. It also hasa majorpart in treating 
subjects withdiabetes type 2when oral anti-diabetic fails to achieve the therapeutic 
goal(Mayfield & White, 2004). Acute illnesses, surgical operations, pregnancy and 
breast feeding, glucose toxicity and other metabolic disorders are conditions (such as 
diabetic ketoacidosis, lactic acidosis and hyperosmolar non-ketotic coma) that 
indicate insulin use. Another insulin indication is the presence of contraindicationsto 
oral anti-diabetic among diabetes type 2 patients(Mayfield & White, 2004; Ministry 
of Health, 2004).One study found that 27% of diabetestype2are using insulin (Koro, 
Bowlin, Bourgeois, & Fedder, 2004).  
Exogenous insulin isfound withdifferent pharmacokinetics, pharmacodynamics,as 
well asphysical and chemical properties(Koda- Kimble et al., 2005).Parenterally 
administered insulin forms are, rapid-acting insulin analogs solution,short-acting 
(regular), intermediate-acting and long-acting (Ultra lente, and insulin glargin) for 
subcutaneous injection (Bolli & Owens, 2000). Other types of insulin is the pre-mixed 
insulin which is aprecise mixture of intermediate-acting and short-acting insulin in 
one vial or insulin pen (Koro et al., 2004).Glycemic control improvement 
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was observed when insulin used in combination with oral anti-diabetic agents among 
patients who failed to achieve glycemic control even by using theupper limit 
combination of oral anti-diabetic drugs (Pugh et al., 1992). It can be used as 
combination with metformin (Ponssen, Elte, Lehert, Schouten, & Bets, 2000), 
sulfonylureas(Wright, Burden, Paisey, Cull, & Holman, 2002), thiazolidenidiones 
(TZDs) (Coniff, Shapiro, Seaton, Hoogwerf, & Hunt, 1995; Derosa et al., 2004), and 
α-glucosidase inhibitors (Coniff et al., 1995). 
1.4 Complications of diabetes 
 
Diabetes is a predisposing factor for many co-morbid complications, and mortality 
in patient with diabetes(Cusick et al., 2005). It has been found that diabetes islisted as 
the sixth cause of mortalityin the United State (> 71,000 deaths per year)(Center of 
Medicare and Medicayd Services (CMS) Public Affairs Office, 2004). The 
DiabetesEpidemiology: Collaborative Analysis of Diagnostic Criteria in 
Europe(DECODE) study group (1999) found that diabetesdoublethe mortality risk 
over 10 years of follow-up compared with non-diabeticcontrols(DECODE, 1999; 
Stancoven & McGuire, 2007).  
Diabetic complications are of two types.Acute complications which include 
hypoglycemia and hyperglycemia, while the other type is the chronic complications 
that are subdivided into two types, macrovascular and microvascular complications. 
Microvascular complications includeretinopathy, neuropathy, and nephropathy, while 
macrovascular complications are cardiovascular events, cerebrovascular diseases, and 
peripheral vascular diseases (Ministry of Health, 2004). Diabetic microvascular 
complicationmorbidity was found to be the primarypredisposing factor of end-stage 
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renal impairment, non-traumatic diabetic foot amputation, and cataractamong adults 
with diabetes(Sheetz & King, 2002). 
In Malaysia, a vast survey on diabetes population showed that 58% ofpatients with 
diabetes were withneuropathy, 57% with retinopathy, and 52% hadmicroalbuminuria. 
It was found that 43-52% of diabetic patients were obese and overweight. The 
majority of them were Malay and Indian females.Moreover, 63-76% had 
hyperlipidemia(Ministry of Health, 2004). About half of patients with diabetes type 2 
are undiagnosed due to silent signs and symptoms (ADA, 2002). As a conclusion, it 
can be said that Malaysian people are at risk of diabetes complications due to the 
delayed diagnosis, uncontrolled glycemia and obesity. 
1.5 Prevention 
Minimizingthe probability of long-term complications of diabetes iscategorized as 
primary, secondary, and tertiary interventions. The primary type means preventing the 
complicationsbefore the onset of diabetes, whereas secondary intervention comes 
afterthe occurrence of diabetes but before the developing diabetic complications. For 
instance,anti-diabetic treatment is prescribed to reachglycemic controlthat leads to 
delay the likelihood of microvascular complications, consequently, decreases the 
rateof deterioration(UKPDS, 1998a). After the occurrence of complications, tertiary 
intervention might play a role but before the advanced end-stageconsequence (Home, 
1996). Using of angiotensin converting enzymeinhibitors (ACEI) was found to 
decrease the end stage renal disease (ESRD) risk.Similarly, it has been found that 
laser photocoagulation decreases the risk of severe loss of vision, while preventive 
foot care decreases the chance of lower limbs amputation in patients with diabetes. 
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Factors such as routine screening, demographic factors, genetic factor, BMI, 
physical activity, history of gestational diabetes are identifiers of peopleat high risk of 
diabetes. Laboratory tests such as insulinsensitivity test and glucose tolerance tests are 
vital for early diagnosis of diabetes. They are known to influence the risk of 
progressionto diabetes mellitus to its complications through early diagnosis 
("Classification and diagnosis of diabetes mellitus and other categories of glucose 
intolerance. National Diabetes Data Group," 1979). 
Adivergentlink between diabetes and moderate exercise was revealed by 
epidemiologic studies (Eriksson & Lindgarde, 1990; Manson et al., 1991). Trials to 
decrease or prevent obesity such as, low fatty food intake, complex carbohydrates 
intake and continuous exercise was associated with reduced insulin resistance and 
incidence of diabetes (Pan et al., 1997).  
It was found that 10% of impaired glucose tolerance might develop to diabetes per 
year, and certain ethnic groups are probably had high risk of diabetes mellitus than 
others. Moreover, this threatmight be seen amongfemales with positive history of 
gestational diabetes (Edelstein et al., 1997). 
Serious complications such as cardiovascular diseases (CVD) are the leading cause 
of death amongpatients with diabetes (UKPDS, 1998b). It has been reported that 
decreasing the risk of 12% of any complications is correlated with reduction of 10 
mmHg in mean systolic blood pressure. In details, 15% reduction was for diabetes-
related death, 13% of microvascular complications, and 11% of myocardial infarction 
(MI) amongpatients with diabetes(UKPDS, 1998a). One studyhas shown that the 
good control for blood pressure is positively associated with the improvement of CVD 
outcomes in patients with diabetes, especially stroke(Chobanian et al., 2003; UKPDS, 
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1998b). Moreover, it decreases the rate of CVD by 33-50%(UKPDS, 1998b). This 
might also delay orprevent diabetic nephropathy (ADA, 2005). 
Microvascular complications such as nephropathy was found in about 20-30% of 
patients with type 2 diabetes (Dobesh, 2006). Untreated neuropathy eventually leads 
to ESRD(Sowers, 2003). A clinical trial found that 2% of diabetes type 2patients 
developed microalbuminuria annually. Moreover, 2.8% of them progressed 
frommicroalbuminuria to macroalbuminuria, and 2.3%progressed from 
macroalbuminuria to high serum creatinine level (≥ 175μmol/l) or hemodialysis 
yearly (U S Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic 
Kidney Disease and End-Stage Renal Disease in the United States, 2012). 
Furthermore, diabetes type 2 nephropathy that cannot be corrected by hemodialysis or 
kidney transplant increases the risk of cardiovascular morbidity and 
mortality(Gerstein et al., 2001).Clinical trials revealed that angiotensin-converting 
enzyme inhibitors (ACEI) andangiotensin II-receptor blockers (ARBs)that suppress 
renin-angiotensin system RAS are useful in preventingdiabetic nephropathy in 
addition to their ability to lower bloodpressure (Lewis et al., 2001; "Should all 
patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-
converting enzyme inhibitors? A meta-analysis of individual patient data," 2001). 
Diabetic retinopathy is a vascular complication with high specificity of both type 1 
and 2 diabetes.Retinopathy prevalence is associated with long exposure to diabetes 
(ADA, 2008). It is the most commonleading cause ofcataracts, glaucoma, and 
blindness among elderly patients with diabetes.Large prospective randomized studies 
approved that intensive diabetes management toachieve controlled glycemia 
wasshowed to prevent and/or delay the onset of diabetic retinopathy(ADA, 2008). 
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One of the most common diabetes complications is diabetic neuropathy. It can be 
defined as peripheral nerve impairment signs and symptoms where other causes of 
peripheral nerve impairment are excluded. This complication accounts 
forhospitalization more oftencompared with other complications of diabetes as it isthe 
most commonleading condition of non-traumaticamputation(Bansal, Kalita, & Misra, 
2006). Silent myocardial infarction might be caused by diabetic autonomic 
neuropathy. In addition, diabetes neuropathy was found toshorten the survival rate, 
causing death in 25%–50% patients with diabetes who had autonomic diabetic 
neuropathy for 5–10 years. It has been demonstrated that theincidence of neuropathy 
increased from 7.5% onadmission to 50% at 25 years follow up(cited in (Bansal et al., 
2006). 
Some studies, (Fontbonne, Berr, Ducimetiere, & Alperovitch, 2001; Gregg et al., 
2000; Wilson et al., 2005; Wilson et al., 2002)have tested the relation of diabetes and 
changes in cognitive function usingdifferent cognitive ways of assessment. However, 
many facts are still unknown about diabetes and change in different cognitive 
domains. Numbers of studies were conducted to clarify this relationship. This 
clarification might also be useful to study the associationof diabetes mellitus with 
Alzheimer’s disease (AD) as cognitive dysfunction is the predisposing factor for 
dementia or AD(Arvanitakis, Wilson, Bienias, Evans, & Bennett, 2004). 
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1.6 Glycosylated hemoglobin (HbA1c), glycemia control and compliance 
Glycosylated hemoglobin is an accurate test to evaluate glycemic control and 
compliance over a3-month period of time. This test is based on measuring the 
percentage of red blood cell (RBC) that has beenirreversibly glycosylated at the β-
chain N-terminal. This test is considered as an assessment for glycemic control for the 
last 2-3 months as RBC life span is around 120 days (Parchman, Pugh, Romero, & 
Bowers, 2007). The normalvalue is between 4-6% of the total hemoglobin (Goldstein 
et al., 2004). Thetargetfor diabetes is < 6.5% (Ministry of Health, 2004).During 
conditions such as anemia, acute or chronic blood loss and uremia HbA1c value is 
affected since these conditions are associated with RBC life span changes. 
Consequently, these changes lead to flawed assessment for glycemic control(Ceriello 
et al., 1991). 
In fact HbA1c test needsspecial preparations to be conducted such as fasting. This 
test should not be considered asa replacement for FPG concentration that is 
importantfor detecting the acute change in blood glucose concentration(ADA, 2010). 
1.7 Cognitive function 
It refers to mental processing thatcomprised attention, memory, solving problems, 
producing and understanding language, and making decisions. The term “cognitive 
dysfunction” is very nonspecific (Ott et al., 1999).Ittypically refers to mild cognitive 
impairment (MCI), delirium, and dementia. MCI refers to deficiency in memory, 
language, executive function, or other cognitive domains and is often considered as 
the early stage of dementia and Alzheimer’s disease(AD) (between normal 
forgetfulness and dementia)(Morris Jc & et al., 2001; Nasreddine et al., 2005).One of 
the causes that lead to the underestimation of its prevalence is that the dysfunction is 
often mild.In fact, cognition is a very multifacetedissue and, formerly, it was denied 
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to exist (Kodl & Seaquist, 2008). Cognitive dysfunction now is studied independently 
as a medical condition or syndrome instead of being under fatigue and depression. 
Cognitive assessment methods werealso improved significantly with proper studies on 
cognitive impairment(Kodl & Seaquist, 2008). While neither MCI nor dementia is an 
immediate threat of morbidity or mortality, dementia is a proven independent 
predictor of functional decline, and institutionalization(Cukierman, Gerstein, & 
Williamson, 2005). Both types of diabetes have been linked with the impaired 
performance on different cognitive domains(Kodl & Seaquist, 2008; Munshi et al., 
2006). The specific pathophysiological changes of cognitive dysfunction in diabetes 
are not entirelyclear yet.Probably, cognitive changes are affected by hyperglycemia, 
hypoglycemia, vascular disease, and insulin resistance (Kodl & Seaquist, 2008).Many 
methodologies to clarify the impact of diabetes on the brain have been developed and 
conducted. Yet, the most fitting methods to detect, manage, and prevent cognitive 
impairment among patients with diabetes have not been defined yet (Kodl & Seaquist, 
2008). 
1.7.1 Cognition and diabetes type 1: Possible underlying mechanism of 
cognitive dysfunction 
 
Multiple factors appear to be affecting the pathological changes that might lead to 
cerebral dysfunction among patients with diabetes type 1. Those factors' contribution 
might be different from one patient to another depending on certain factors like co-
morbidity conditions, age, gender, and glycemic control of each patient. 
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1.7.1(a)Cerebral dysfunction in diabetes type1 
Type 1 diabetes patients are prescribed insulin exogenously. Unluckily, by all 
means and dosage forms, exogenous insulinis unable toachieve the optimum insulin 
levelcompletely as in normally functioning pancreas. Consequently, those patients 
have the possibility to show blood glucose levels fluctuations during the day, 
fromhyperglycemia to hypoglycemia and vice versa. These fluctuations are dependent 
on the amount and food quality, timing, dose of insulin administered, and the 
exercise. These fluctuations of glucose level may affect cognitive performance since 
normal brain function depends on adequate content of glucose level in blood 
circulation, (ADA, 2002).Nowadays, there are significant evidences that acute 
disturbance in blood glucose level affects the functioning of the central nervous 
system (CNS).This may present itself as structural and neurophysiological 
changes(Weinger & Jacobson, 1998),however, the clinical signs and symptomsare 
still heterogeneous. This study will take a look into the prevalence of cognitive 
impairment and the possible risk factors that have been concerned in cognitive 
function changing in diabetes that may trigger cognitive dysfunction. 
1.7.1(b)Cerebral neuroradiological changes  
Studies concerning brain neuroradiological changes were few. These studies 
conducted in patients with type 1 diabetes involved a case-control 
methodology(Lunetta et al., 1994), whereas others compared patients to standard 
values(Araki et al., 1994). In a case-control study design, central and peripheral 
changes have been noticed(Lunetta et al., 1994). Since the majority of MRI reports of 
patients type 1 diabetic were within normal spectrum,some researchers did not read 
this as a specific characteristic of diabetes itself (Chabriat et al., 1994). The MRI 
brain in patients with diabetes has been suggested to resemble that of  ageing process, 
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howeverit was shown to appearin younger patients than in controls(Araki et al., 
1994).In general, focal lesions were found in the subcortical white-matter (Ferguson 
et al., 2003). Hyper-intensity periventricular white-matter lesions, in particular, small 
punctuate lesions, were present in one third of the scanned patients. These changes 
was found to be associated with positive retinopathy history (Ferguson et al., 2003). 
1.7.1(c)Case-control cognitive performance 
Wide spectrum cognitive tests revealed that type 1 diabetes patients have 
shownmoderate cognitiveimpairment compared to controls. By using diversity of 
neuropsychological tests, many studies showed that patients with type 1 diabetes 
performedcompared to controls. Almost all these studies showed negativeimpact on 
attention, psychomotor speed, general intellectual functioning and delayed 
memory(Stewart, Prince, & Mann, 2003). A detailed analysis showed that elderly 
patients with diabetes type 1 performed to some extent poorer on the majority of 
cognitive domains. These poor performances did not come withnoticeableradiological 
changes on MRI brain. Yet, it was important to report the level of performance of 
these elderlywith diabetes type 1 compared with control individualswhich wasparallel 
to the results in younger adults with type 1 diabetes (Brands, Biessels, de Haan, 
Kappelle, & Kessels, 2005).Severe cognitive dysfunction have been reported in case 
studies(Gold et al., 1994). 
1.7.1(d)Repeated episodes of severe hypoglycemia 
A number of cross-sectionalresearches reported a link between frequently occurred 
severe hypoglycemia episodes and MCI(Gold et al., 1994; Sachon et al., 1992). 
However, other studies did not confirm this fact (DCCT, 1996; Kramer et al., 1998; 
Reichard, Pihl, Rosenqvist, & Sule, 1996). The Diabetes Control and Complications 
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Trial (DCCT, 1996) was a longitudinal study with 6.5 years average of follow-up that 
studied the effect of intensive diabetes mellitus treatment on microvascular 
complications among large sample size patients with type 1 diabetes. It was found that 
the onset as well as extent diabetic complications such as neuropathy and retinopathy 
are delayed by intensive diabetes therapyin comparisonwith conventional treatment. 
The risk of episodes of severe hypoglycemia is increased by threefold using intensive 
anti-diabetic treatment; however, it was not associated with neuropsychological 
deficit(Reichard, Britz, & Rosenqvist, 1991).  Results suggested that the 
harmfulimpactof recurring severe hypoglycemia episodes on cognitive performance is 
limited. 
1.7.1(e)Diabetes duration and the presence of other complications 
In most cases,diabetes duration and the extent of metabolic control determine the 
development of diabetic complications (retinopathy, neuropathy and nephropathy). 
The association of these complications and cognitive performance was reported by 
several studies (Ferguson et al., 2003; Ryan et al., 2006). The aforementioned 
associationexplains that the brain is liable to the same changes that cause these other 
diabetic complications. In fact, thoroughdata on the relation between diabetes duration 
metabolic control and cognitive function are deficient. The suggestion of 
thesusceptibility of elderly patients to the diabetes effect on the brainby time makes 
the missing data on elderly crucial issue. 
1.7.1(f)Depression and anxiety morbidity in diabetes 
Depression and anxiety disorders was shown to have negative impact on cognitive 
function especially among diabetes patients that might be attributed to the 
functionally defective neurotransmitters in the brain (Anderson, Freedland, Clouse, 
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&Lustman, 2001). A 42-study meta-analysis showed that diabetes doubles the odd 
ratio of cognitive dysfunction. Moreover, the difference between type 1 and 2 odd 
ratios was not recognized (Anderson et al., 2001).   
1.7.1(g)Hyperglycemia 
Like in peripheral tissues, hyperglycemia leads to increase the glucose level in the 
brain. The extra glucose will convert to fructose and sorbitol (Bhardwaj, Sandhu, 
Sharma, & Kaur, 1999). Animal studies revealed that the high concentration of 
sorbitol and fructose in the Central Nervous System (CNS) has been associated to 
phosphoinositide and diacylglycerol metabolism changes (Bhardwaj et al., 1999). In 
addition to Ca
2+ 
homeostasis changes (Biessels, ter Laak, Hamers, & Gispen, 2002), 
this will influence the protein kinases activity in the CNS. Animal models 
demonstrated that protein kinases A and C activities were revealed to be 
elevated(Bhardwaj et al., 1999). Moreover, otheranimal studies showed that the 
formation of advanced glycation end products is caused by elevated glucose 
levels(Brownlee, 1992). These end products was found in the CNS of diabetic rodents 
(Ryle, Leow, & Donaghy, 1997). Also, glucose toxicity was found to result from 
thediscrepancybetweenreactive oxygen free radicals production and scavengers(Van 
Dam & Bravenboer, 1997). Animal studies on diabetic rats demonstrated high 
concentrations of lipid peroxidation by-products in addition to vertebral oxidative 
damage(Kumar & Menon, 1993; Mooradian, 1995). Moreover, it was approved that 
the activities of superoxide dismutase and catalase enzymesthat wereinvolved in the 
antioxidant protectionpathway of the brain,were decreased (Mooradian, 1995). 
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1.7.1(h)Cerebrovascular changes 
Structural and functional changes in brain tissue that result from diabetes increase 
the risk of stroke(Beckman, Creager, & Libby, 2002), and atherosclerotic diseases 
(Mankovsky, Metzger, Molitch, & Biller, 1996). Both conditions might affect 
cognitive functions. Functional changes in the vasculatureof the brain that have been 
linked with diabetes type 1 include decreased blood flow in brain, in particular 
regions in the brain (Keymeulen et al., 1995).Cerebral atrophy is another issue that is 
generally modest among patients with type 1 which might affect cognitive functions. 
This issue needs further investigations (Sabri et al., 2000). 
1.7.1(i)The role of severe prolonged hypoglycemic episodes 
Brain damage may be provoked by prolonged hypoglycemia. This can be explained 
by the uncontrolled release of glutamate and aspartate (excitatory amino-acids), 
activate calcium influx which will lead to proteolytic enzymes activation. This 
process will causeneurons damage (Perros & Frier, 1997). In addition, experimental 
design found that the duration of hypoglycemia episodes also affects brain damage 
severity (Chabriat et al., 1994).  During the glucose shortage period in the brain, 
alternatives such as amino-acids and ketones will act as fuel resource. These 
alternatives will lead to brain damage(Chabriat et al., 1994).  
1.7.1(j)The insulin role in the brain 
The hippocampus is a major brain structure that play an important role in memory 
function, especially the long-term consolidation of information (forming, organizing 
and storing).A considerable number of insulin receptors are present in hippocampus 
(Park, 2001). It has been found that insulin can modulate memory function by several 
mechanisms. Insulin is found to be helpful glucose utilization in certain areas in 
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brain,such as the hippocampus. In addition, it has been suggested that glucose play an 
important role to promote memory tasks(Park, 2001). Suggestion was made also 
about the indirect role of insulinto promote the neurotransmitters activity such as 
acetylcholine by stimulating the uptake of glucose by neurons (Park, 2001). These 
neurotransmitters were found to have major role in memory consolidating (Park, 
2001). 
Under abnormal conditionssuch as diabetes type 1,endogenous insulin secretion by 
the β-cells is almost absent. In such condition, the use of exogenous insulin 
subcutaneously asa replacement is the treatment of choice. Consequently, the level of 
insulin in the blood is elevated(Nijs, Radder, Poorthuis, & Krans, 1990). Insulin needs 
to pass the blood brain barrier to reach and bind to its receptors in the brain to exert its 
effect. This process is affected by diabetes mechanism as a disease. Animal study 
showed that insulin transport through the blood brain barrier is increased during 
hyperglycemic, hypoinsolinimic diabetic type 1 rodent (Banks, Jaspan, & Kastin, 
1997).In addition, it has been reported that insulin-receptors binding in the brain of 
these rodentsdoes not differ from controls (Marks & Eastman, 1989). In addition,it 
was shown to be lower in high insulin level, high glucose level rodents 
brains(Figlewicz et al., 1985).  
In fact, types of diabetes might be differentin insulin signaling.It is well understood 
that diabetes type 2is highly associated with insulin resistance, whereas diabetes type 
1 is associated with this insulin resistance to a lesser extentthan type 1(DeFronzo, 
Hendler, & Simonson, 1982).The literature gave an explanation to a part of the 
distinctive cognitive profiles of these two types. For instance, in diabetes type 1, long 
term storage of information and recall of information seems to be comparatively intact 
unlikediabetes type 2 patients. Long term storage of information and attainment of 
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information are mainly processed in the hippocampal region in the brain that has high 
number of insulin receptors that make it extra susceptible to any defect in insulin 
action (Squire & Alvarez, 1995). 
1.7.2 Cognition and diabetes type 2 
1.7.2(a)Demographic factors 
Recently, it was obvious that diabetes type 2 affectsthe CNS in many 
pathways(Gispen & Biessels, 2000). The literature dealt with the cognitive 
functioning and diabetes type 2relationship, in particular, with certain cognitive 
domains such as verbal memory or complex information processing(Awad, Gagnon, 
& Messier, 2004). These studies differ in terms of demographic criteria of 
participants, like age, gender distribution, diabetic parameters (diabetic complications, 
diabetes treatment, and diabetic duration) (Awad et al., 2004; Stewart & Liolitsa, 
1999). Different methodologies were adopted in those studies. In addition, 
differentcognitive domains were the point of interest. Regardless of these differences, 
the most common result is that mild to moderate cognitive dysfunction (information 
processing speed, episodic memory and, to a less extent, mental flexibility) is 
associated with diabetes type 2 (Awad et al., 2004; Stewart & Liolitsa, 1999). 
1.7.2(b)Glycemic control and its related problems 
Studies tested relations between cognitive functioning and different disease 
variables demonstrated that cognitive impairment was associated with worse glycemic 
control (Strachan, Deary, Ewing, & Frier, 1997). Cognitive dysfunction is also 
thought to be enhanced by other risk factors (cardiovascular, cerebrovascular disease, 
and depression). Furthermore, age has not been used as a dependent variable in nearly 
most of studies.Mostly, the literature dealt with  patients who were among older age 
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group(Ryan & Geckle, 2000). As patients with type 2 getting older, other conditions 
such as hypertension, macro- and microvascular complications, atherosclerotic 
changes will be developed(Manschot et al., 2006; Ryan & Geckle, 2000). Those 
conditions may produce further cognitive dysfunction. 
Some epidemiological studies revealed a relation between diabetes and dementia 
(Leibson et al., 1997; Ott et al., 1999). The mediators that accelerate cognitive 
impairment in patients with diabetes type 2 are not clear yet. Studies in this field 
concerned both, diabetic complications (for example, hypertension and depression) 
and glycemic control (Allen, Frier, & Strachan, 2004; Stewart & Liolitsa, 1999). Few 
studiesconsidered hypertension as a vital risk factor for cognitive 
impairment(Alexopoulos et al., 1997; Hassing et al., 2004; Stewart & Liolitsa, 1999). 
On the other hand, other studies did not support these findings (Kanaya, Barrett-
Connor, Gildengorin, & Yaffe, 2004; Luchsinger et al., 2005). 
1.7.2(c) Cerebral radiological changes  
Abnormal MRI cerebral was highly considered in only few studies in patients with 
diabetes type 2. Case-control studies addressed that subcortical and cortical atrophy 
and symptomatic and silentbrain infarcts were in found patients with diabetes type 2 
compared to controls (Araki et al., 1994; Manschot et al., 2006; Vermeer et al., 
2003). It was shown that abnormal MRI changes were associated with cognitive 
dysfunction, mostly, atrophy, lesions, and infarcts in the white-matter. 
1.7.2(d) Neuropsychological changes 
Type 2 is also associated with depressive symptoms (Anderson et al., 2001; 
Lockwood, Alexopoulos, & van Gorp, 2002) that might be also associated with 
cognitive dysfunction (Lockwood, Alexopoulos, & van Gorp, 2002; (Elderkin-
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Thompson et al., 2003). Also, depressive symptoms were addressed to be related to 
white-matter abnormalities (Jorm et al., 2005). Moreover, it is associated with the 
extent of diabetic complications which has been addressed as vascular depression 
(Alexopoulos et al., 1997). Among elderly subjects, the co-occurrence of the three 
conditions (depressive symptoms, cognitive dysfunction, and vascular abnormalities) 
was addressed as vascular dementia or pseudo-dementia. In another word, areversible 
cognitive dysfunction is associated with geriatric vascular depression (Baldwin, 
Gallagley, Gourlay, Jackson, & Burns, 2006). 
1.7.2(e) Type 2 diabetes treatment 
A study revealed that Roziglitazone might improve cognition in patient with 
Alzheimer disease (Brodbeck et al., 2008), and metformin monotherapy might 
increase the formation of beta-amyloid protein, a predisposing factor of cognitive 
dysfunction and Alzheimer disease. It has been found that metformin combination 
therapy with TZDs, or with insulin is considered as a cognitive function protector 
(Chen et al., 2009).  
In conclusion, the need for further studies to reveal the predisposing factor(s) for 
cognitive impairment among patients with diabetes is mandatory. It is important to go 
further andinvestigate the diversity between diabetes type 1 and type 2 regarding their 
association with cognition changes. It was shown that the two types of diabetes are 
characterized by distinctivemodels of cognitive dysfunction. Further illumination is 
needed to see whether these distinctive models are due to the role of insulin in the 
brain in each type, or due to the fact that studies on type 2 diabetes and oral anti-
diabetic drugswere mostly performed with elderly patients in comparison with those 
studies on diabetes type 1. 
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1.8 Problem Statement 
Diabetes mellitus have been linked with shortages in certain number of mental 
processing domains of cognitive performance with unclear mechanism. This disease 
thought to be one of the predisposing factors of cognitive impairment. At the same 
time, diabetes is a self-management metabolic disease that needs intact cognition. The 
importance of this appears in dealing with diabetes treatment and its high complexity. 
For example patient with diabetes need intact cognition to deal with conditions such 
asmonitoring of blood glucose level, diet regimen, and compliance to medications and 
their complex timetable.Considering the importance of intact cognition in these 
conditions, patientswho show cognitive problemshave significant possibility to face 
difficulties to manage their conditions. For example, patients might forget about their 
medication timing or dosing. They may also have difficulty in treating acute 
conditions associated with diabetes treatment such as hypoglycemia. In addition, 
those patients considered as incapable to reportor even realize both conditions, the 
cognitive problems and/or thecomplexityofmanaging diabetes on their own. For that 
reason, medical care givers might be unaware of cognitive impairment (Munshi et al., 
2006), and that calls for need for cognitive assessment. 
This studytend to combine cognitive data, data on psychological well-being,and 
diabetes clinical information using a reasonably sufficient number of patients with 
type 1 and type 2 diabetes. In addition, the same data were collected from a number of 
control subjects. The controls were with certain criteria, age, and educational level-
matched control participants.Small sample MRI screening data analysis was also 
adopted. This combination, in the researcher's opinion, adds new insights to the 
present literature. This study will raise the following questions: 
